BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18677113)

  • 1. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
    Popowicz GM; Czarna A; Holak TA
    Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
    Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoinhibition of MDMX by intramolecular p53 mimicry.
    Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
    Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
    Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
    Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary interaction between MDMX and p53 core domain inhibits p53 DNA binding.
    Wei X; Wu S; Song T; Chen L; Gao M; Borcherds W; Daughdrill GW; Chen J
    Proc Natl Acad Sci U S A; 2016 May; 113(19):E2558-63. PubMed ID: 27114532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of how stress-induced MDMX phosphorylation activates p53.
    Chen X; Gohain N; Zhan C; Lu WY; Pazgier M; Lu W
    Oncogene; 2016 Apr; 35(15):1919-25. PubMed ID: 26148237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MdmX protects p53 from Mdm2-mediated degradation.
    Jackson MW; Berberich SJ
    Mol Cell Biol; 2000 Feb; 20(3):1001-7. PubMed ID: 10629057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
    Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
    Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X
    Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MdmX represses E2F1 transactivation.
    Wunderlich M; Ghosh M; Weghorst K; Berberich SJ
    Cell Cycle; 2004 Apr; 3(4):472-8. PubMed ID: 14739777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity.
    Nomura K; Klejnot M; Kowalczyk D; Hock AK; Sibbet GJ; Vousden KH; Huang DT
    Nat Struct Mol Biol; 2017 Jul; 24(7):578-587. PubMed ID: 28553961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Interrogation of the N-Terminal Lid of MDMX in p53 Binding via Native Chemical Ligation.
    Chen X; Lu W
    Chem Pharm Bull (Tokyo); 2016; 64(7):1004-8. PubMed ID: 27373663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
    Liu Z; Olejniczak ET; Fesik SW
    Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.